2 active not recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 2 |
Follow CD20 Positive: new trials by email Literature Review of CD20 Positive trials Research Report on CD20 Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - CD19 Positive, CD20 Positive | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 24 | 2019-10-04 | 2026-08-20 |
| Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma Carboplatin, Carfilzomib, Etoposide - CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Active not recruiting | Roswell Park Cancer Institute | 29 | 2014-04-17 | 2026-08-26 |
Lymphoma, Large B-Cell, Diffuse (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, B-Cell (1)
CT-P10 (1) · Carboplatin (1) · Cyclophosphamide (1) · Disulfides (1) · Etoposide (1) · Ifosfamide (1) · Immunoglobulin G (1) · Immunotherapy, Adoptive (1) · Rituximab (1) · carfilzomib (1) · fludarabine phosphate (1) · tocilizumab (1)
Jonsson Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (2)
Francisco Hernandez-ILizaliturri (1) · Sarah Larson, MD (1)
R01CA136907 (1)